ATEA Pharmaceuticals, Inc.
Clinical trials sponsored by ATEA Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing antiviral therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
- Can a new drug tame hepatitis e? a first human trial begins Results expected Dec 2026 (estimated)
- New hep c combo aims to match top therapy in phase 3 showdown Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Can a new drug tame hepatitis e? a first human trial begins
Disease control Recruiting nowThis early-stage trial tests an experimental drug called AT-587 in healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for hepatitis E, a liver infection that currently has no approved therapy. Participants recei…
Phase 1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug interaction study for opioid treatments launches
Knowledge-focused Recruiting nowThis early-stage study looks at how a new antiviral drug combination (BEM/RZR) affects the levels of two common opioid addiction treatments—buprenorphine/naloxone and methadone—in healthy adults. Researchers will give participants their usual opioid therapy plus the antiviral dru…
Phase 1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC